|
 Background |
| Founded in 1952, our company was first a subsidiary of the France-based Bottu laboratories, before it became independent 30 years later. |
| |
| Activity |
The Bottu company manufactures locally, packages and imports about a hundred products intended to Human therapy. These products are marketed according to agreements signed with renowned laboratories:
|
| • BOTTU SA |
| • THERAPLIX (SANOFI-AVENTIS) |
| • DEXO |
| • BOEHRINGER INGELHEIM |
| • CLL PHARMA |
| • ETHYPHARM, |
| • FOURNIER (DEBAT), |
| • JOHNSON ET JOHNSON
(MARTIN) |
| • PROCTER & GAMBLE
(NATIVELLE), |
| • OMEGA PHARMA FRANCE, |
| • IREX (SANOFI-SYNTHELABO) |
| • RIOM-CERM |
| • GRUNENTHAL |
| • MILLET INNOVATION |
| • ODOST |
|
With an annual output of 33 million units for a 40 million capacity and a turnover of 449 million dirhams, Bottu is ranked today among the biggest Moroccan laboratories. Its leader product, Doliprane, ranks first in terms of the number of units sold in the local market.
|
| Bottu has set up an internal organization which is commensurate with its vision. Strengthened by a workforce of 456 people, the company gives particular importance to in-house training and the self-actualization of its personnel. |
| |
| Medical promotion |
| Promoting Bottu's products among physicians is carried out by an important team of medical representatives. Young, motivated and trained, these professionals are monitored by dynamic and efficient supervision. In fact, the increase of the company's annual turnover remains one of the best in the business (15 to 20% annually). |
| |
| Methods of distribution |
80% of the products are distributed to 53 wholesalers throughout the country; whereas 15% are directly sold to pharmacists and 5% to public service.
|
